Overcoming Barriers to Adoption of Glucagon-Like Peptide-1 Antagonists in India

Despite the promising introduction of Glucagon-like Peptide-1 (GLP-1) analogs in the Indian market for managing diabetes and obesity, their uptake remains limited due to several factors: high costs, lack of outpatient insurance coverage, side effects, limited long-term data on cardiovascular and renal safety, and healthcare professionals' reluctance to prescribe them. This study aims to explore these barriers and propose innovative strategies to enhance the adoption of GLP-1 analogs in India. By applying Rogers' Diffusion of Innovations theory, the research will analyze the adoption process and develop targeted strategies to overcome identified challenges, ultimately benefiting a significant segment of the population struggling with diabetes and obesity.